GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » Scaled Net Operating Assets

Biotricity (Biotricity) Scaled Net Operating Assets : -0.62 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biotricity Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biotricity's operating assets for the quarter that ended in Dec. 2023 was $5.40 Mil. Biotricity's operating liabilities for the quarter that ended in Dec. 2023 was $9.63 Mil. Biotricity's Total Assets for the quarter that ended in Sep. 2023 was $6.82 Mil. Therefore, Biotricity's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was -0.62.


Biotricity Scaled Net Operating Assets Historical Data

The historical data trend for Biotricity's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity Scaled Net Operating Assets Chart

Biotricity Annual Data
Trend Aug14 Aug15 Dec16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.05 -3.29 -2.16 0.26 -0.05

Biotricity Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 -0.13 -0.48 -0.86 -0.62

Competitive Comparison of Biotricity's Scaled Net Operating Assets

For the Medical Devices subindustry, Biotricity's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotricity's Scaled Net Operating Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Biotricity's Scaled Net Operating Assets falls into.



Biotricity Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biotricity's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2023 )
=(Operating Assets (A: Mar. 2023 )-Operating Liabilities (A: Mar. 2023 ))/Total Assets (A: Mar. 2022 )
=(5.941-6.81)/16.678
=-0.05

where

Operating Assets(A: Mar. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6.511 - 0.57
=5.941

Operating Liabilities(A: Mar. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=26.356 - 14.436 - 5.11
=6.81

Biotricity's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(5.401-9.626)/6.824
=-0.62

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5.486 - 0.085
=5.401

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=32.214 - 12.456 - 10.132
=9.626

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotricity Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Biotricity's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotricity (Biotricity) Business Description

Traded in Other Exchanges
Address
275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.
Executives
Chester P White director 447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon director 1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq director, 10 percent owner, officer: CEO and Chairman of the Board C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou officer: Chief Financial Officer C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065

Biotricity (Biotricity) Headlines